Skip to Content

ASCO 2026: PRIME-ROSE and Implementation of Precision Cancer Medicine in Europe

Live Fagereng, PhD, Researcher and Project Manager at Oslo University Hospital, presented the PRIME-ROSE initiative at ASCO 2026, describing a scalable European framework for implementing precision cancer medicine through investigator-initiated platform trials. The network includes 11 national studies built on harmonized protocols and cross-border data sharing to accelerate evidence generation and support integration of molecularly guided therapies into clinical care and reimbursement pathways across Europe.

Live Fagereng

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top